Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells

Human Gene Therapy

Volumn 17, Issue 12, 2006, Pages 1241-1253

  Gutermann, Anja ^a,c   Mayer, Elfriede ^a   Von Dehn Rothfelser, Karin ^a   Breidenstein, Claudia ^a   Weber, Mihaela ^a   Muench, Martina ^a   Gungor, Denis ^a   Suehnel, Juergen ^b   Moebius, Ulrich ^a   Lechmann, Martin ^a  

^a MediGene   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; NV 1020; ONCOLYTIC HERPES VIRUS; OXALIPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; COLON CARCINOMA; COLORECTAL CANCER; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER CANCER; LIVER METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLAQUE FORMING CELL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR MODEL; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MURINAE;

EID: 33845786476     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.1241     Document Type: Article

References (42)

1. ADUSUMILLI, P.S., CHAN, M.K., CHUN, Y.S., HEZEL, M., CHOU, T.C., RUSCH, V.W., and FONG, Y. (2006). Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol. Ther. 5, 48-53.
2. ADVANI, S.J., SIBLEY, O.S., SONG, P.Y., HALLAHAN, D.E., KATAOKA, Y., ROIZMAN, B., and WEICHSELBAUM, R.R. (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5, 160-165.
3. ADVANI, S.J., CHUNG, S.M., YAN, S.Y., GILLESPBE, G.Y., MARKERT, J.M., WHITLEY, R.J., ROIZMAN, B., and WEICHSELBAUM, R.R. (1999). Replication- competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 59, 2055-2058.
4. BENENCIA, F., COURREGES, M.C., CONEJO-GARCIA, J.R., MOHAMED-HADLEY, A., ZHANG, L., BUCKANOVICH, R.J., CARROLL, R., FRASER, N., and COUKOS, G. (2005). HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther. 12, 789-802.
5. BENNETT, J.J., DELMAN, K.A., BURT, B.M., MARIOTTI, A., MALHOTRA, S., ZAGER, J., PETROWSKY, H., MASTORIDES, S., FEDEROFF, H., and FONG, Y. (2002). Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 9, 935-945.
6. BRAUN, A.H., ACHTERRATH, W., WILKE, H., VANHOEFER, U., HARSTRICK, A., and PREUSSER, P. (2004). New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100, 1558-1577.
7. CHAHLAVI, A., TODO, T., MARTUZA, R.L., and RABKIN, S.D. (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1, 162-169.
8. COUKOS, G., MAKRIGIANNAKIS, A., MONTAS, S., KAISER, L.R., TOYOZUMI, T., BENJAMIN, I., ALBELDA, S.M., RUBIN, S.C., and MOLNAR-KIMBER, K.L. (2000). Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther. 7, 275-283.
9. COZZI, P.J., BURKE, P.B., BHARGAV, A., HESTON, W.D., HURYK, B., SCARDINO, P.T., and FONG, Y. (2002). Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 53, 95-100.
10. DELMAN, K.A., BENNETT, J.J., ZAGER, J.S., BURT, B.M., MCAULIFFE, P.P., PETROWSKY, H., KOOBY, D.A., HAWKINS, W.O., HORSBURGH, B.C., JOHNSON, P., and FONG, Y. (2000). Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 11, 2465-2472.
11. DELMAN, K.A., ZAGER, J.S., BHARGAVA, A., PETROWSKY, H., MALHOTRA, S., EBRIGHT, M.I., BENNETT, J.J., GUSANI, N.J., KOOBY, D.A., ROBERTS, G.D., and FONG, Y. (2004). Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. Hepatology 39, 1525-1532.
12. DRESSLER, V., MULLER, G., and SUHNEL, J. (1999). CombiTool: A new computer program for analyzing combination experiments with biologically active agents. Comput. Biomed. Res. 32, 145-160.
13. EISENBERG, O.P., ADUSUMILLI, P.S., HENDERSHOTT, K.J., YU, Z., MULLERAD, M., CHAN, M.K., CHOU, T.C., and FONG, Y. (2005). 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest. Surg. 9, 1068-1077; discussion 1077-1069.
14. HEISE, C., LEMMON, M., and KIRN, D. (2000). Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. 6, 4908-4914.
15. HOUGHTON, J.A., HARWOOD, F.G., and TILLMAN, D.M. (1997). Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc. Natl. Acad. Sci. U.S.A. 94, 8144-8149.
16. JAIN, R.K., DUDA, D.O., CLARK, J.W., and LOEFFLER, J.S. (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40.
17. LOVAT, P.E., RANALLI, M., BERNASSOLA, F., TILBY, M., MALCOLM, A.J., PEARSON, A.D., PIACENTINI, M., MELINO, G., and REDFERN, C.P. (2000). Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int. J. Cancer 88, 977-985.
18. MARSHALL, J. (2005). The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol. 32, S43-S47.
19. MCAULIFFE, P.F., JARNAGIN, W.R., JOHNSON, P., DELMAN, K.A., FEDEROFF, H., and FONG, Y. (2000). Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J. Gastrointest. Surg. 4, 580-588.
20. MEIGNIER, B., LONGNECKER, R., and ROIZMAN, B. (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J. Infect. Dis. 158, 602-614.
21. MEIGNIER, B., MARTIN, B., WHITLEY, R.J., and ROIZMAN, B. (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313-321.
22. MIDGLEY, R., and KERR, D. (1999). Colorectal cancer. Lancet 353, 391-399.
23. MIZUTANI, Y., NAKANISHI, H., YOSHIDA, O., FUKUSHIMA, M., BONAVIDA, B., and MIKI, T. (2002). Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur. J. Cancer 38, 167-176.
24. MULLER, D.B., RAFTERY, M.J., KATHER, A., GIESE, T., and SCHONKICH, G. (2004). Frontline: Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus. Eur. J. Immunol. 34, 941-951.
25. PAWLIK, T.M., NAKAMURA, H., MULLEN, J.T., KASUYA, H., YOON, S.S., CHANDRASEKHAR, S., CHIOCCA, E.A., and TANABE, K.K. (2002). Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95, 1171-1181.
26. PETROWSKY, H., ROBERTS, G.D., KOOBY, D.A., BURT, B.M., BENNETT, J.J., DELMAN, K.A., STANZIALE, S.F., DELOHERY, T.M., TONG, W.P., FEDEROFF, H.J., and FONG, Y. (2001). Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J. Virol. 75, 7050-7058.
27. POST, D.E., FULCI, G., CHIOCCA, E.A., and VAN MEIR, E.G. (2004). Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. 4, 41-51.
28. RAKI, M., KANERVA, A., RISTIMAKI, A., DESMOND, R.A., CHEN, D.T., RANKI, T., SARKIOJA, M., KANGASNIEMI, L., and HEMMINKI, A. (2005). Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 12, 1198-1205.
29. REID, T.R., FREEMAN, S., POST, L., McCORMICK, F., and SZE, D.Y. (2005). Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 12, 673-681.
30. RIES, S.J., and BRANDTS, C.H. (2004). Oncolytic viruses for the treatment of cancer: Current strategies and clinical trials. Drug Discov. Today 9, 759-768.
31. SHIMOYAMA, S., MOCHIZUKI, Y., KUSADA, O., and KAMINISHI, M. (2002). Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing Hgand on gastric and colon cancers in vitro. Int. J. Oncol. 21, 643-648.
32. STRATER, J., HINZ, U., WALCZAK, H., MECHTERSHEIMER, G., KORETZ, K., HERFARTH, C., MOLLER, P., and LEHNERT, T. (2002). Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 8, 3734-3740.
33. TILLMAN, D.M., PETAK, I., and HOUGHTON, J.A. (1999). A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res. 5, 425-430.
34. TOYOIZUMI, T., MICK, R., ABBAS, A.E., KANG, E.H., KAISER, L.R., and MOLNAR-KIMBER, K.L. (1999). Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10, 3013-3029.
35. TYMINSKI, E., LEROY, S., TERADA, K., FINKELSTEIN, D.M., HYATT, J.L., DANKS, M.K., POTTER, P.M., SAEKI, Y., and CHIOCCA, E. A. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 65, 6850-6857.
36. VARGHESE, S., and RABKIN, S.D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967-978.
37. VETTORI, M.V., GOLDONI, M., CAGLIERI, A., POU, D., FOLESANI, G., CECCATELLI, S., and MUTTI, A. (2006). Antagonistic effects of methyl-mercury and PCB153 on PC12 cells after a combined and simultaneous exposure. Food Chem. Toxicol. 44, 1505-1512.
38. VIALE, P.H., FUNG, A., and ZITELLA, L. (2005). Advanced colorectal cancer: Current treatment and nursing management with economic considerations. Clin. J. Oncol. Nurs. 9, 541-552.
39. WANG, Q., WANG, X., HERNANDEZ, A., HELLMICH, M.R., GATALICA, Z., and EVERS, B.M. (2002). Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J. Biol. Chem. 277, 36602-36610.
40. WONG, R.J., KIM, S.H., JOE, J.K., SHAH, J.P., JOHNSON, P.A., and FONG, Y. (2001). Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg. 193, 12-21.
41. WONG, S.F. (2005). Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 27, 684-694.
42. YOU, L., YANG, C.T., and JABLONS, D.M. (2000). ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60, 1009-1013.